Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

Myeloma and infection: clinical and lived perspectives webinar

Myeloma Patients Europe (MPE) will host a webinar on “Myeloma and infection: clinical and lived perspectives” on Thursday, 11th September 2025 from 17:00 – 18:00 CEST. Aimed at myeloma patients, carers and patient advocates, the webinar will feature presentations on infection risk and prevention in myeloma, and a patient’s experiences of infection in myeloma. Jackie Quinn,…

Read more

The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patients

Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP – their scientific advisory committee) on 23 May 2025. Marketing authorisation means that…

Read more

New guidelines for the treatment and the management of myeloma and smouldering myeloma

On July 7th, 2025, new clinical management guidelines for myeloma and smouldering myeloma were published in Nature Reviews Clinical Oncology by myeloma experts. These guidelines are written to guide doctors and healthcare professionals in myeloma and smouldering myeloma diagnosis, treatment and follow-up, based on the most up-to-date scientific knowledge. The last treatment guidelines were published in…

Read more

EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myeloma

On the 19th June 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended  marketing authorisation for daratumumab for patients with high-risk smouldering myeloma. Daratumumab is a monoclonal antibody marketed by Johnson & Johnson as Darzalex®. This medicine has been designed to recognise and bind to the CD38 protein, which is found on the surface…

Read more

EHA 2025 | Expert interviews

During the European Hematology Association (EHA) Annual Congress 2025, MPE conducted a series of expert interviews covering the most interesting updates in myeloma. These interviews focused on important research results and their potential to improve patient survival and quality of life. Dr. Sundar Jagannath discusses the long-term remission and survival for relapsed/refractory patients after treatment with ciltacabtagene…

Read more

Join our EHA 2025 highlights webinar

To help patients and advocates digest the most important myeloma news from the European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, Myeloma Patients Europe (MPE) will host a webinar on Tuesday, 24 June at 17:00 CET. The session will be led by Dr. Ulf-Henrik Mellqvist, Haematologist and Associate Professor at…

Read more

Myeloma EHA 2025 preview

The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma. Myeloma Patients Europe (MPE) will be attending the congress to…

Read more

EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patients

On the 23 May 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of two belantamab mafodotin combinations for the treatment of patients with relapsed and/or refractory myeloma. The first combination is with bortezomib (a proteasome inhibitor) plus the steroid dexamethasone (BVd) in patients who have received at least one prior therapy.…

Read more
February

March 2026

April
MO
TU
WE
TH
FR
SA
SU
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Events for 1st March
No Events
Events for 2nd March
No Events
Events for 3rd March
No Events
Events for 4th March
No Events
Events for 5th March
No Events
Events for 6th March
No Events
Events for 7th March
No Events
Events for 8th March
No Events
Events for 9th March
No Events
Events for 10th March
No Events
Events for 11th March
No Events
Events for 12th March
No Events
Events for 13th March
No Events
Events for 14th March
No Events
Events for 15th March
No Events
Events for 16th March
No Events
Events for 17th March
No Events
Events for 18th March
No Events
Events for 19th March
No Events
Events for 20th March
No Events
Events for 21st March
No Events
Events for 22nd March
No Events
Events for 23rd March
No Events
Events for 24th March
No Events
Events for 25th March
No Events
Events for 26th March
No Events
Events for 27th March
No Events
Events for 28th March
No Events
Events for 29th March
No Events
Events for 30th March
No Events
Events for 31st March
No Events